Clinical Trials / Research Studies
Solid Tumors Retinoblastoma New Diagnosis
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
- Ages: ≤ 30 years old
This phase II trial studies the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that has come back. Larotrectinib may stop the growth of cancer cells with TRK fusions by blocking the TRK enzymes needed ...More
Contact Us
To learn more about available clinical trials related to solid tumors, contact us at cancer@cchmc.org or 513-636-2799.
Related Studies
- Retinoblastoma Relapse / Refractory
- Neurofibromatosis Sarcoma New Diagnosis
- Neurofibromatosis Sarcoma Relapse / Refractory
- Neurofibromatosis NF2
- Plexiform Neurofibroma
- Neurofibromatosis OPG/Low Grade Glioma
- Neurofibromatosis Other
- Melanoma New Diagnosis
- Melanoma Relapse / Refractory
- Germ Cell Tumor New Diagnosis
- Germ Cell Tumor Relapse / Refractory
- All Other Solid Tumors
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2022 Cincinnati Children's Hospital Medical Center. All rights reserved.
